The association of oral androgenic-anabolic steroids and life-threatening disease.
The use of androgenic anabolic steroids in the therapeutic dose range by strength athletes is well documented. The benign side effects of these drugs are well known but more disturbing are the increasingly frequent reports of potentially fatal diseases in association with the therapeutic use of these agents. A review is made of the clinical evidence indicating a direct association between androgenic steroids and peliosis hepatis, heptocellular carcinoma and acute myelogenous leukemia, all potentially fatal disorders.
D000328:Adult; D006528:Carcinoma, Hepatocellular / Q000139:chemically induced*; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D004305:Dose-Response Relationship, Drug; D005199:Fanconi Anemia / Q000188:drug therapy; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced*; D008111:Liver Function Tests; D008113:Liver Neoplasms / Q000139:chemically induced*; D008297:Male; D013178:Sports Medicine; D045165:Testosterone Congeners / Q000009:adverse effects* / Q000627:therapeutic use
D045165:Testosterone Congeners